Research ArticleClinical Investigation
Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Manuel Weber, Nader Hirmas, Karina Kostbade, Sebastian Bauer, Martin Schuler, Marit Ahrens, Hans-Ulrich Schildhaus, Christoph Rischpler, Hong Grafe, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler and Rainer Hamacher
Journal of Nuclear Medicine May 2022, 63 (5) 727-734; DOI: https://doi.org/10.2967/jnumed.121.262468
Justin Ferdinandus
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Pedro Fragoso Costa
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Lukas Kessler
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Manuel Weber
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Nader Hirmas
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Karina Kostbade
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Sebastian Bauer
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Martin Schuler
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Marit Ahrens
4Medical Clinic II, University Hospital Frankfurt, Frankfurt am Main, Germany;
Hans-Ulrich Schildhaus
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
5Department of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany;
Christoph Rischpler
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Hong Grafe
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Jens T. Siveke
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
6Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Medicine Essen, Essen, Germany; and
7Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center (DKFZ), Heidelberg, Germany
Ken Herrmann
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Wolfgang P. Fendler
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, and Uital Essen, Essen, Germany;
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
Rainer Hamacher
2German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Manuel Weber, Nader Hirmas, Karina Kostbade, Sebastian Bauer, Martin Schuler, Marit Ahrens, Hans-Ulrich Schildhaus, Christoph Rischpler, Hong Grafe, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler, Rainer Hamacher
Journal of Nuclear Medicine May 2022, 63 (5) 727-734; DOI: 10.2967/jnumed.121.262468
Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Manuel Weber, Nader Hirmas, Karina Kostbade, Sebastian Bauer, Martin Schuler, Marit Ahrens, Hans-Ulrich Schildhaus, Christoph Rischpler, Hong Grafe, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler, Rainer Hamacher
Journal of Nuclear Medicine May 2022, 63 (5) 727-734; DOI: 10.2967/jnumed.121.262468
Jump to section
Related Articles
Cited By...
- No citing articles found.